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we hope to offer a pre-admission psychosocial evaluation to
the entire pediatric SCT population.526
Instituting the Very Immunocompromised Alert (VIP)
Protocol in a Community Hospital for a New Blood and
Marrow Program
Joy Schindler. Oncology BMT, St. David’s South Austin Medical
Center, Austin, TX
Timely administration of antibiotics in highly immunocom-
promised patients presenting to the emergency room with
neutropenic fever reduces hospital stays, mortality due to
sepsis, and costs. Current guidelines recommend that he-
modynamically unstable patients receive broad-spectrum
antibiotics within 30 minutes of arrival to the Emergency
Department. For hemodynamically stable patients, this in-
terval increases to one hour. As a community hospital
launching a new blood and marrow transplant program, it
was imperative that the Emergency Department and
Oncology staff follow best practice in managing neutropenic
fever.
The transplant team, the Emergency Department, and nurse
educators were enlisted to ensure that the ED physicians, ED
triage nurses, hospitalists, critical care physicians and ICU
nurses, and the new BMT/Oncology unit nurses recognized
the unique concerns related to managing complex hemato-
logic malignancy and blood and marrow transplant patients.
The Very Immune Compromised Patient Alert (VIP) protocol
was implemented. The VIP Program consists of patient and
family education, a VIP card that is presented at the ED, ED
staff education, and a rapid triage and intervention protocol.
Departments impacted by the new protocol, including Lab-
oratory, Microbiology and Radiology received additional
training. The protocol for high-risk patients presenting to the
Emergency Department with neutropenic fever was set into
place in December 2013 two months before the ﬁrst patient
scheduled for transplant.
Post-implementation data for 23 patients demonstrated a
median door to antibiotic time of 52 minutes (range 27e107
minutes).
Next steps: Continue to investigate barriers to rapid
deployment of this protocol in febrile neutropenic patients.
Develop and implement strategies for improvement in
diagnosis and ﬁrst dose of empirical therapy.
Continue to track datawith each VIP patient presenting to
the ED and report to Cancer Committee and Quality Council
quarterly.527
30 Day Readmissions Rate- How Many Ways Can We
Calculate Thee?
Sheila Seraﬁno 1, Julie Curtis 2, Laura Bernhard 3,
Navneet S. Majhail 4, Ronald Sobecks 5. 1 Blood & Marrow
Transplant, Cleveland Clinic, Cleveland, OH; 2 Blood & Marrow
Transplant, The Cleveland Clinic, Cleveland, OH; 3 Blood &
Marrow Transplant Program, Cleveland Clinic Foundation,
Cleveland, OH; 4 Blood & Marrow Transplant Program,
Cleveland Clinic, Cleveland, OH; 5Hematologic Oncology and
Blood Disorders, Taussig Cancer Institute, Cleveland Clinic,
Cleveland, OHPurpose: To create a process/method for monitoring the 30
day readmission rate for BMT patients. Our program has
been active in attempting to reduce the 30 day readmission
rate since 2011. Initial reported metrics were available at the
Cancer Center level. Initiatives were undertaken to drill
down to only BMT readmissions enabling us to ascertain a
relevant rate for our program.
Methods: Data from 2009 & 2010 were analyzed to deter-
mine the 30 day readmission base rate. Data was categorized
according to autologous, allogeneic inpatient and allogeneic
outpatient transplants. Only readmissions occurring after
index transplant hospitalization were included. Also
included were readmissions to other services (ICU, leukemia
unit etc.). 30 day readmission numbers (numerator) were
easily obtained through a hospital quality outcomes data-
base; however, determining the denominator necessitated a
manual analysis from 2 years’ worth of weekly meeting mi-
nutes. Readmission rates were monitored monthly at the
BMT Quality Assurance meeting. We have experienced many
limitations in calculating and maintaining readmission rates
including:
Data pulled from the BMT database for monthly reporting
proved prohibitive due to time needed to clean up data.
Different reporting platforms at the hospital level for both
discharges and readmissions.
Time lag in data availability for discharged patients from
the hospital database.
Gaps in data posting to hospital database, results in
multiple data pulls.
Necessity to reconcile/double check data monthly.
There are many variables to consider when determining
which readmissions/discharges to include (small changes in
either category can reﬂect a large change in rate):
Pre transplant admit/discharge within 30 days of trans-
plant admission (eg, BMT admit within 30 days of discharge
after leukemia induction therapy).
Hospital metrics are unit based and may not include BMT
patients cared for outside the BMT unit.
ED admits.
Admissions for Observation only.
Admission/discharge from an outside hospital.
Weighing the difference between the hospital calculated
readmission rate and that which is beneﬁcial from a BMT
quality/patient safety perspective.
Fields analyzed monthly include: number of days be-
tween admissions, readmission length of stay (LOS), index
admission LOS; readmission reason, comorbidity score,
location admitted from etc., we are always attempting to
identify a focal point to direct efforts to reduce the read-
mission rate.
Conclusion: Determine which calculation factors are most
meaningful for your BMT program. Develop a system which
is easy to maintain on a routine basis and in as real-time as
possible. Engage as many disciplines within your program to
contribute input for readmission impact projects. Resolve the
fact that it may be necessary to sustain a hospital metric and
a BMT metric.528
A Network Approach to Creation and Maintenance of
Standardized Standard Operating Procedures
Paul J. Shaughnessy 1, Maria Custodio 2, Charles F. LeMaistre 3,
Tonya Cox 4, Sandra Shearin 5. 1 Adult Blood and Marrow
Transplant, Texas Transplant Institute, San Antonio, TX;
2Medical City Dallas Hospital, Dallas, TX; 3 BMT Program,
Abstracts / Biol Blood Marrow Transplant 21 (2015) S355eS373S362Sarah Cannon, Nashville, TN; 4 Sarah Cannon, Nashville, TN;
5 Blood Cancer Network, Sarah Cannon, Nashville, TN
The Sarah Cannon Blood Cancer Network (SCBCN) consists
of 6 programs in the US performing over 850 HSCTs annu-
ally. A goal was established to develop a single set of stan-
dard operating procedures (SOP) that would support
Network members. This standardization project was guided
by four principles: Quality, Efﬁciency, Democracy, and
Collaboration.
A BMT physician and Program Quality Manager were
established as co-chairs of the SOP Standardization Com-
mittee. Each BMT program identiﬁed work group repre-
sentatives from clinical, collection and processing. Processes
were established including identifying the SOP team leads
and development teams, collection of more than 300 SOPs
from each BMT program, drafting of standardized SOPs,
soliciting program input, dispute resolution, and approval.
The SOP Review Process was coordinated by a project
manager.
The SOP standardization process resulted in the creation of
approximately 70 Network SOPs. The project of SOP
standardization was started in October of 2011, and the
standardized SOPs were made available for local approval
and implementation in early 2013. Programs had the
freedom to customize the Network SOPs for program-
speciﬁc needs but were not to remove core content. SOP
maintenance including routine review is managed by a
continuing Network SOP committee with representation
from clinical, collection and processing laboratory staff in
each program. This committee meets monthly by confer-
ence call and reviews SOPs per an annual review calendar.
One SOP is selected each quarter and monitored for “drift”
from the Network template SOP. Five of the network
programs underwent FACT inspection and found the
network SOPs to be helpful in preparing for and passing
the inspection.
Network-wide development required resource and time
commitment from all programs. A common quality plan hel-
ped all institutions meet regulatory requirements and com-
mon outcome measures. Ongoing commitment and review of
the SOPs is required to prevent institutional drift and update
SOPs to meet any changes in regulatory requirements.529
A Model for Building a New Adult Blood and Marrow
Program
Nikki Sikes 1, Lynne Jean DeBerry 2. 1 Administration, St.
David’s South Austin Medical Center, Austin, TX; 2Director,
Service Line Director, St David’s South Austin Medical Center,
Austin, TX
Austin, Texas is one of the fastest growing cities in the United
States. Cancer care in Austin is driven by strong community
physicians, dominated by Texas Oncology. In 2010, several
foundations studied cancer care in the Austin community
and found the largest service gap to be in Hematopoietic
Stem Cell Transplantation (HSCT). At the end of 2012, four
distinct entities, St. David’s South Austin Medical Center,
Texas Oncology, Texas Transplant Institute at Methodist
Hospital in San Antonio, and Sarah Cannon came together to
create an HSCT program in Austin. With each providing a
unique and needed component, the Austin program was
started in February 2014, completed their ﬁrst FACT inspec-
tion as a non-contiguous clinical program in conjunctionwith Texas Transplant Institute in July 2014, and is expected
to achieve full FACT accreditation by the Fall of 2014. The
collaboration between the four parties has led to faster-than-
expected program creation and ensured the quality, service,
and clinical excellence imperative in the treatment of HSCT
patients.
Eachmember of the collaboration team brought a needed set
of skills, knowledge, and effort that were essential in the
successful implementation. These included:
St. David’s South Austin Medical Center: The hospital, along
with its sponsor organizations, Hospital Corporation of
America (HCA) and the St. David’s Foundation, provided the
infrastructure needed, including the staff, equipment, sup-
plies and a new unit and clinic speciﬁcally designed for the
care of HSCT patients.
Texas Transplant Institute/Methodist Hospital: Texas Trans-
plant Institute, a well-established provider of HSCT services,
provided the clinical expertise through physician coverage,
guidance, nurse/technician education, and quality manage-
ment. Cell Therapy Processing services are provided by
Methodist Hospital.
Texas Oncology: The Austin-based community oncologists
established patient requirements, smoothed transitions, and
actively supported the program.
Sarah Cannon Blood Cancer Network: The SCBCN provided
standardized policies, procedures, and quality management
plans based on the best practices of the network facilities.
This collaborative organization composes a model of inte-
gration for new programs going forward. As more commu-
nities grow in their need for clinically-excellent stem cell
transplants close to home, this process provides a roadmap
for program creation in the future.
St. David’s South Austin Medical Center Adult Blood and
Marrow Transplant Program is a non-contiguous program
in partnership with Texas Transplant Institute of Meth-
odist Hospital that share a single medical director. Both
programs share common protocols, procedures, quality
management systems and staff training and compe-
tencies. Both programs participate regularly to review
clinical results: morbidity and mortality, quality
improvement and performance.530
NMDP Transplant Center Network Survey of Payer Policy
Issues
Alicia Silver. Payer Policy & Legislative Relations, NMDP/Be
The Match, Minneapolis, MN
The National Marrow Donor Program (NMDP) works to
facilitate life-saving unrelated donor transplants for patients
with hematologic malignancies like leukemia, lymphoma
and sickle cell disease. The NMDP’s transplant center
network includes 143 centers across the country along with
donor centers, apheresis and collections centers as well as
cord blood banks. The NMDP surveyed its transplant center
network to better understand the scope of payer policy is-
sues transplant centers are facing. Fifty-six transplants
responded to the survey for a response rate of 39%. The
survey had four main focus areas: Medicare, Medicaid,
commercial payers and the Affordable Care Act (ACA). These
four areas have each been problematic for transplant cen-
ters for various reasons in the areas of reimbursement,
beneﬁt restrictions, covered disease indications and guide-
lines for transplantation and network inclusion. The survey
was conducted to formally assess the current standing and
